International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 6 (November-December 2025) Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 6
November-December 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Methotrexate: The Cornerstone Drug in Autoimmune and Neoplastic Diseases

Author(s) Komal Gaike, Prof. Umme Roman Shaikh
Country India
Abstract Methotrexate (MTX) is a cornerstone medication in both oncology and rheumatology/autoimmune disease treatment. Originally developed as a folate-antagonist antimetabolite for malignant disease, MTX's low-dose immunomodulatory and anti-inflammatory effects have made it the anchor drug for conditions such as Rheumatoid arthritis (RA), psoriasis and other autoimmune disorders. This review provides a detailed overview of its mechanism of action, pharmacokinetics, therapeutic indications, adverse effects, contraindications, drug-interactions, monitoring recommendations, and recent research developments. Understanding MTX's multifaceted roles and risks is critical to optimize therapy and minimise toxicity.
Methotrexate (MTX) is an anti-metabolite commonly administered during chemotherapy and as an immunosuppressant for autoimmune diseases. This activity reviews the indications, mechanism of action, and contraindications for methotrexate as a treatment for neoplastic and autoimmune conditions. Adverse events, off-label uses, pharmacokinetics, administration methods, and key monitoring considerations are discussed to optimize patient outcomes. Relevant drug interactions and clinical toxicology are also highlighted to enhance safe and effective use.
Field Medical / Pharmacy
Published In Volume 7, Issue 6, November-December 2025
Published On 2025-11-27
DOI https://doi.org/10.36948/ijfmr.2025.v07i06.62145
Short DOI https://doi.org/hbdsmr
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 5Cover Page Vol 7 Isu 4Cover Page Vol 7 Isu 3

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com